Hereditary retinal degenerations comprise a diverse group of inherited genetic defects in one or more retinal or retinal pigment epithelial cellular proteins. Traditionally, anatomic classification based on clinical and histopathologic phenotype has been used to organize these disorders. In the modern era of advanced molecular biological techniques and genetic screening the current classification system may soon become obsolete, due to the fact that significant overlap between different retinal degenerations has been observed, resulting from variation in gene expression, common genetic pathways, and variable inheritance patterns. In this article, we review the various clinical disease entities, emphasize a genetic classification system, and give special attention to recent advances in molecular biology and gene therapy.
Interestingly, RP has been associated with all forms of mendelian inheritance patterns. It appears that autosomal dominant is the most common identifiable inheritance pattern, present in approximately 15-25% of cases. Autosomal recessive inheritance is also common, as is the absence of any family history. X-linked and mitochondrial variants have also been described. There are over 100 genes that have been identified and implicated in the disease. consisting of a subretinal microphotodiode array. 15 The device was found to be safe with many patients developing evidence of improved visual function. Currently, the most advanced device employs an epiretinal microarray sponsored by Second Sight Medical Products and is currently in phase II clinical trials. This employs a tiny camera mounted on the patient's eyeglasses that transmits a digital image to the intraocular microarray, which in turn transmits the image to electric impulses that can be detected by the retina (see Figure 1 ). 16 
Leber Congenital Amaurosis
Leber's congenital amaurosis (LCA) is a group of visual disorders characterized by infantile onset, recessive inheritance, and severe visual loss secondary to severe rod-cone dysfunction. 17, 18 Classically these diseases have been classified as infantile-onset RP. The incidence is rare, occuring in between one in 30,000 and one in 80,000 live births. Although the disorder is heterogenous in terms of underlying defect, molecular diagnosis is important for genetic counseling and possible treatment. 21, 24 In the pre-genomic era, there were no 
X-linked Retinoschisis
X-linked retinoschisis, or inherited splitting of the foveal nerve fiber layer, is the leading cause of macular degeneration in young males, with a prevalence between one in 15,000 and one in 30,000 males.
30,31
The disorder follows typical X-linked inheritance with no male-male transmission, carrier females, and affected males. 32 The disorder is caused by several identified mutations in retinoschisin, a retinal protein product of the gene RS1. [33] [34] [35] RS1 maps to the distal arm of the X-chromosome (Xp22). Retinoschisin is a secreted protein that likely participates in cell-cell interaction. Genetic defects cause failure of secretion or failure of extracellular polymerization and cell adhesion.
Clinically, the disorder has a heterogenous set of features. There appears to be a bimodal distribution of age at diagnosis. 36 
Stargardt's Disease
Stargardt's disease, or fundus flavimaculatus, is an autosomal recessively inherited form of macular degeneration and is the most common macular dystrophy in patients under 50 years of age. 43 The disorder affects approximately one in 10,000 individuals. The most common genetic defect is in ABCA4 on chromosome 1p, whose product is the ATP-binding cassette transporter protein. 44 The 46 Visual field testing is often normal early in the disease course but progresses to central scotoma. 47 ERG is typically normal early in the disease but may progress to prolonged implicit times or generalized depression of amplitude late in the disease course. 48 Histopathologic studies support the notion that the underlying genetic defect leads to the accumulation of lipofuscin, 49 a metabolic waste product and subsequent retinal and RPE dysfunction as a result of photoreceptor cell loss. [49] [50] [51] Although genetic advances are being made in understanding Stargardt's disease, the molecular mechanism by which the disease manifests are not well understood. Currently there is no proven treatment; further research will be needed to investigate the feasibility of gene therapy for Stargardt's disease. 
